Please assess the completion status of the following clinical trial:

Trial Title: OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Successively recruit all patients who receive stent implantation;~2. Intended use of standard DAPT with the combination of aspirin 100mg once daily and clopidogrel 75mg once daily for at least 12 months;~3. Patient aged \>18 years and ≦80 years old;~4. Signed inform consent.~Exclusion criteria:~1. Allergy or intolerance to study drugs;~2. History of gastrointestinal or intracranial bleeding;~3. Need for anticoagulant therapy;~4. High risk of bleeding (e.g., myelodysplasia, baseline platelet count \< 80 × 109/L);~5. Hemoglobin \< 90g/L;~6. Active malignancy or life expectancy \< 1 year;~7. Patients with other conditions made them unsuitable to be recruited at the discretion of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLOP-150 (Type: EXPERIMENTAL): clopidogrel 150mg once daily
- CLOP+CILOST (Type: EXPERIMENTAL): clopidogrel 75mg once daily plus cilostazol 100mg twice daily
- TICAG (Type: EXPERIMENTAL): ticagrelor 90mg twice daily
- CON(conventional DAPT) (Type: ACTIVE_COMPARATOR): clopidogrel 75mg once daily
- Non-HOPR (Type: ACTIVE_COMPARATOR): clopidogrel 75mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).